Cargando…

2562. Retrospective Analysis of Cefepime Intravenous Push versus Extended Infusion for the Treatment of Neutropenic Fever

BACKGROUND: The outcomes associated with intravenous push (IVP) cefepime compared to extended infusion (EI) have not yet been studied. The objective of this study was to evaluate the effectiveness of IVP versus EI cefepime in patients with neutropenic fever. METHODS: This was a retrospective, single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rust, Thomas J, Krause, Tracy M, Saw, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678425/ http://dx.doi.org/10.1093/ofid/ofad500.2179

Ejemplares similares

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
por: Smith, Susan E., et al.
Publicado: (2023)

Cefepime extended infusion versus intermittent infusion: Clinical and cost evaluation
por: Khole, Aalok V., et al.
Publicado: (2023)

Cefepime in critically ill patients: continuous infusion versus intermittent regimen
por: Georges, B, et al.
Publicado: (2001)

1364. Effect of Cefepime Prophylaxis on Bacterial Bloodstream Infections in Neutropenic Patients with Acute Myelogenous Leukemia
por: Dassner, Aimee, et al.
Publicado: (2020)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, Adriana, et al.
Publicado: (2012)

2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
por: Tran, Kieu-Nhi, et al.
Publicado: (2019)

1022. The Role of Baseline Body Temperature in Neutropenic Fever
por: Corsi, Anthony J, et al.
Publicado: (2022)

Neutropenic Fever
por: Baluch, Aliyah, et al.
Publicado: (2019)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam
por: Gerlach, Anthony T., et al.
Publicado: (2019)

602. Intravenous Push Versus Intravenous Piggyback Administration of Cephalosporin Antibiotics: Impact on Safety, Workflow, and Cost
por: Lee, Ryan, et al.
Publicado: (2021)

2562. Implementation of Current Event Assignments to Engage Students and Enhance Public Health and Infectious Diseases Awareness in a Doctor of Pharmacy Program
por: Ernst, Erika
Publicado: (2019)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

Evaluation of a Risk Stratification Guideline for the Treatment of Neutropenic Fever in Oncology Patients
por: Wollenziehn, Amber, et al.
Publicado: (2017)

1535. Utility of CT Abdomen in Evaluation of Neutropenic Fever in Patients with Hematological Malignancies
por: Al-Ward, Ruaa, et al.
Publicado: (2018)

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023)

Specification pour colliers selon plan EA.8088.2562.D
Publicado: (1975)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

2679. Factors Associated with Multidrug-resistant Gram-Negative Bacteremia in Acute Leukemia Patients with Neutropenic Fever, a Retrospective Study
por: Chaiittiporn, Dudrudee, et al.
Publicado: (2019)

1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2018)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

2805. Extended-Infusion versus Intermittent-Infusion Piperacillin/tazobactam for High Minimum Inhibitory Concentration Pseudomonas aeruginosa Infections
por: Shifko, Carlee R, et al.
Publicado: (2023)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, A, et al.
Publicado: (2013)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

Antibiotic practice and stewardship in the management of neutropenic fever: A survey of US institutions
por: Arya, Swarn, et al.
Publicado: (2023)

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model
por: Lasko, Maxwell J, et al.
Publicado: (2020)

Blood Culture in Neutropenic Patients with Fever
por: Meidani, Mohsen, et al.
Publicado: (2012)

COVID-19 presenting as neutropenic fever
por: Spencer, Hunter C., et al.
Publicado: (2020)

Neutropenic Fever in the Intensive Care Unit
por: Stephens, R. Scott
Publicado: (2019)

280. The Impact of a Revised Neutropenic Fever Guideline on Vancomycin-Resistant Enterococcus Rates in Pediatric Oncology Patients
por: Karandikar, Manjiree, et al.
Publicado: (2018)

1090. Practicing Antimicrobial Stewardship: De-escalating Empiric Antibiotics in Patients with Acute Myelogenous Leukemia and Neutropenic Fever
por: Fuller, Risa, et al.
Publicado: (2019)

Activity of the Novel Extended-spectrum β-Lactamase Inhibitor AAI101 in Combination with Cefepime Towards a Challenge Panel of Acinetobacter baumannii
por: Morrissey, Ian, et al.
Publicado: (2017)

478. Outcomes of Extended-Spectrum β-Lactamase-Producing Escherichia coli Bloodstream Infection in Neutropenic Patients with Hematological Malignancies
por: Aslam, Sadaf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nsgafi4oc30cqb615o0lma8t8j